Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab as Neoadjuvant and Adjuvant Therapy for Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
NCT03765918Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Pembrolizumab + Standard of Care (SOC) with Standard of Care (SOC) (2 arms). Primary endpoint: Event-free Survival at 66 months. Started Dec 2018; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03765918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765918.